Recent Research Published in Peer Review Journals

Srikumar Mallick: Outcome of patients with idiopathic pulmonary fibrosis (IPF) ventilated in intensive care unit;
Respiratory Medicine: Available online 17 July 2008.

Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, Thomeer M, Utz JP, Khandker RK, McDermott L, Fatenejad S: Treatment of Idiopathic Pulmonary Fibrosis With Etanercept: An Exploratory, Placebo-Controlled Trial;   Am J Respir Crit Care Med. 2008 Jul 31; [Epub ahead of print]; Pubmed ID: 18669816

Vidya Krishnan, MD, MHS; Meredith C. McCormack, MD, MHS; Stephen C. Mathai, MD, MHS; Shikhar Agarwal, MD; Brittany Richardson; Maureen R. Horton, MD; Albert J. Polito, MD; Nancy A. Collop, MD; and Sonye K. Danoff, MD, PhD: Sleep Quality and Health-Related Quality of Life in Idiopathic Pulmonary Fibrosis; DOI 10.1378/chest.08-0173; Chest published online July 14, 2008

Yuko Waseda, Masahide Yasui, Yoriko Nishizawa, Kanako Inuzuka, Hazuki Takato, Yukari Ichikawa, Atsuro Tagami, Masaki Fujimura and Shinji Nakao: Angiotensin II Type 2 receptor antagonist reduces bleomycin-induced pulmonary fibrosis in mice; Respiratory Research 2008, 9:43

Karin M. Vermeulen PhD, Elisabeth M. TenVergert PhD, Erik A.M. Verschuuren MD, PhD, Michiel E. Erasmus MD, PhD and Wim van der Bij MD, PhD; Pre-transplant Quality of Life Does Not Predict Survival After Lung Transplantation; © 2008 International Society for Heart and Lung Transplantation

Munson, Jeffrey C. MD; Kreider, Mary Elizabeth MD, MS The Role of Surgical Biopsy in the Evaluation of Interstitial Lung Disease; Clinical Pulmonary Medicine. 15(4):201-209, July 2008.

Xinping Yue, Xian Li, Hong T. Nguyen, Dawn R. Chin, Deborah E. Sullivan§, and Joseph A. Lasky:: Transforming Growth Factor-ί1 Induces Heparan Sulfate 6-O-Endosulfatase 1 Expression in Vitro and in Vivo; J. Biol. Chem., Vol. 283, Issue 29, 20397-20407, July 18, 2008

Barnes PJ (2008): A blood test for lung fibrosis? PLoS Med 5(4): e98. doi:10.1371/journal. pmed.0050098

PLoS Med 2008: MMP1 and MMP7 as Potential Peripheral Blood Biomarkers in Idiopathic Pulmonary Fibrosis; Rosas IO, Richards TJ, Konishi K, Zhang Y, Gibson K, et al. (2008) PLoS Med 5(4): e93. doi:10.1371/journal.pmed.0050093

Am J Path (2008): A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosis American Journal of Pathology, 2008; 172(3):583-91; J.M. Englert & colleagues, UPMC (Pittsburgh, PA)

Radiology: Idiopathic Pulmonary Fibrosis: Physiologic tests, quantitative CT indexes, and CT scores as predictors of mortality. Abstract-only. Radiology, 2008; 246(3):935-940). A.C. Best & colleagues, Univeristy of Colorado (Denver, CO)

Euro Resp J: Pulmonary Hypertension in patients with pulmonary fibrosis awaiting lung transplant; abstract-only. European Respiratory Journal, 2007; 30(4):715-21. A.F. Shorr & colleagues, Washington Hospital Center (Washington, D.C.)

Am J Respir Crit Care Med: BUILD-1: A Randomized, Placebo Controlled Trial of Bsentan in Idiopathic Pulmonary Fibrosis; Abstract-only. Am J Respir Crit Care Med Vol 177:75-81

Chest 2007: Lung Allocation Score for Lung Transplantation: Impact on Disease Severity and Survival; Gries, Mulligan, Edleman, Raghu, Curtis, Goss. Chest 2007: 132; 1954-1961 DOI: 10.1378/chest.07-1160

Am J Respir Crit Care Med: Role of Alpha (1)-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Abstract-only. Am J Respir Crit Care Med 2007; 176(12):1243-1250.

Am J Respir Crit Care Med Vol 176 pp 277-284 2007 Mortality from Pulmonary Fibrosis Increased in the United States from 1993-2002 Amy Olsen, M.D., M.S.P.H. National Jewish Medical and Research Center

Am J Respir Crit Care Med Vol 175 pp 1101-1103 2007 Op Ed Taking the "Idio" Out of Idiopathic Pulmonary Fibrosis Author David M. Center, MD, Boston University, Boston, MA

N Engl J Med 2007;356:1317-26. Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis: Mary Y. Armanios, M.D., Julian J.-L. Chen, Ph.D., Joy D. Cogan, Ph.D., Jonathan K. Alder, B.A., Roxann G. Ingersoll, B.S., Cheryl Markin, B.S., William E. Lawson, M.D., Mingyi Xie, B.S., Irma Vulto, B.S., John A. Phillips III, M.D., Peter M. Lansdorp, M.D., Ph.D., Carol W. Greider, Ph.D., and James E. Loyd, M.D

Am J Respir Crit Care Med Vol 175. pp 45–54, 2007 Gene Expression Profiling of Familial and Sporadic Interstitial Pneumonia Authors: Ivana V. Yang, Lauranell H. Burch, Mark P. Steele, Jordan D. Savov, John W. Hollingsworth, Erin McElvania-Tekippe, Katherine G. Berman, Marcy C. Speer, Thomas A. Sporn, Kevin K. Brown, Marvin I. Schwarz, and David A. Schwartz

Respiratory Medicine: Volume 101, Issue 6, June 2007, Pages 1350-1354 Patient experiences with pulmonary fibrosis Collard, Tino, Noble, Shreve, Michaels, Carlson, Schwarz

J Respir Crit Care Med : Incidence and Prevalence of Idiopathic Pulmonary Fibrosis: Ganesh Raghu, M.D., Derek Weycker, Ph.D., John Edelsberg, M.D., M.P.H., Williamson Z. Bradford, M.D., Ph.D., Gerry Oster, Ph.D.: Published on June 29, 2006 as doi:10.1164/rccm.200602-163OC

D. Jastrzebski, A. Gumola, R. Gawlik, J. Kozielski Dyspnea and Quality of Life in Patients with Pulmonary Fibrosis After Six Weeks of Respiratory Rehabilitation: Journal of Physiology and Pharmacology 2006, 57, Supp 4, 139.148

A Critical Assessment of Treatment Options for Idiopathic Pulmonary Fibrosis: Nirav R. Shah, Paul Noble, Robert M. Jackson, Talmadge E. King, Jr., Steven D. Nathan, MariaPadilla, Ganesh Raghu, Melissa Bruce Rhodes, Marvin Schwarz, Gregory Tino, Robert W. Dubois SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES: 2005; 22: 167-174

Bosentan versus placebo in interstitial lung disease secondary to systemic sclerosis: The BUILD 2 study JR Seibold, CM Black, CP Denton, DE Furst, L Guillevin, LJ Rubin, A Wells, P Charef, S Roux, H Chadha-Boreham: Poster Session at the Annual Meeting of the American Thoracic Society

Interferon gamma 1-b Therapy in Idiopathic Pulmonary Fibrosis*: A Metaanalysis
Ednan K. Bajwa, MD; Najib T. Ayas, MD MPH; Michael Schulzer, MD, PhD; Edwin Mak, BSC; Jay H. Ryu, MD; and Atul Malhotra, MD, FCCP: Chest 2005 128: 203-206

Archives of Internal Medicine June 2005 Vol. 142 Number 12 – The Clinical Course of Patients with Idiopathic Pulmonary Fibrosis: Fernando J. Martinez, MD; Sharon Safrin, MD; Derek Weycker, PhD; Karen M. Starko, MD; Williamson Z. Bradford, MD, PhD; Talmadge E. King Jr., MD; Kevin R. Flaherty, MD; David A. Schwartz, MD; Paul W. Noble, MD; Ganesh Raghu, MD

Journal of Clinical Investigation Vol 114 No. 3 August 2004: Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis: Robert M. Strieter, MD et.al

Jacobs S, Lindell K. Idiopathic Pulmonary Fibrosis: New guidelines for diagnosing and managing the disease demand a fresh approach to nursing care. Am J Nursing 2003: Vol 103 No 4: 32-41

American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment (international consensus statement). Am J Respir Crit Care Med . 2000;161:646-664. Gross TJ, Hunninghake, GW. Idiopathic Pulmonary Fibrosis N Engl J Med 2001; 345: 517-525.

A Physician's Guide to Idiopathic Pulmonary Fibrosis.

References Used to Create the coalitionforprf.org Web Site

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment (international consensus statement). Am J Respir Crit Care Med. 2000;161:646-664.

2. Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157:199-203.

3. Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998;157:1063-1072.

4. Hubbard R, Johnston I, Britton J. Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study. Chest. 1998;113:396-400.

5. Johnston ID, Prescott RJ, Chalmers JC, Rudd RM, for the Fibrosing Alveolitis Subcommittee of the Research Committee of the British Thoracic Society. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. Thorax. 1997;52:38-44.

6. Mapel DW, Hunt WC, Utton R, Baumgartner KB, Samet JM, Coultas DB. Idiopathic pulmonary fibrosis: survival in population based and hospital based cohorts. Thorax. 1998;53:469-476.

7. Strieter RM, Keane MP. Cytokine biology and the pathogenesis of interstitial lung disease. In: King TE Jr, ed. New Approaches to Managing Idiopathic Pulmonary Fibrosis. New York, NY: American Thoracic Society; 2000:27-35.

8. Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134:136-151.

9. Leslie KO. The pathology of idiopathic pulmonary fibrosis. In: King TE Jr, ed. New Approaches to Managing Idiopathic Pulmonary Fibrosis. New York, NY: American Thoracic Society; 2000:8-13.

10. Katzenstein ALA, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157:1301-1315.

11. American Thoracic Society. International guidelines for the selection of lung transplant candidates. Am J Respir Crit Care Med. 1998;158:335-339.

12. Mason RJ, Schwarz MI, Hunninghake GW, Musson RA. Pharmacological therapy for idiopathic pulmonary fibrosis: past, present, and future. Am J Respir Crit Care Med. 1999;160:1771-1777.

13. du Bois RM. Potential future approaches to the treatment of idiopathic pulmonary fibrosis. In: King TE Jr, ed. New Approaches to Managing Idiopathic Pulmonary Fibrosis . New York, NY: American Thoracic Society; 2000:52-57.